Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib

Journal of Controlled Release

Volumn 104, Issue 1, 2005, Pages 167-179

  Park, Kyeongsoon ^a   Je, Hoon Yang ^b   Choi, Yongdoo ^a   Lee, Chulkyu ^c   Sang, Yoon Kim ^b   Byun, Youngro ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Shinpoong Pharmaceutical Co   (South Korea)

Author keywords

All trans retinoic acid; Biodegradable microspheres; Carcinogenesis; Celecoxib; Inflammation

Indexed keywords

BIOLOGICAL ORGANS; BLOOD; CELLS; CHEMOTHERAPY; COLLAGEN; CONTROLLED DRUG DELIVERY; DEPOSITION; METABOLISM;

ALL-TRANS RETINOIC ACID (ATRA); CHEMOPREVENTIVE AGENTS; HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC); ORAL CARCINOGENESIS;

DRUG PRODUCTS;

4 NITROQUINOLINE 1 OXIDE; CELECOXIB; COLLAGEN; MACROGOL; MICROSPHERE; POLYGLACTIN; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TREATMENT OUTCOME;

EID: 18144384195     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.01.013     Document Type: Article

References (43)

1. J.C. Gillis, and K.L. Goa Tretinoin: a review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia Drugs 50 1995 897 923
2. S. Chanchevalap, M.O. Nandan, D. Merlin, and V.W. Yang All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5 FEBS Lett. 578 2004 99 105
3. A.M. Simeone, and A.M. Tari How retinoids regulate breast cancer cell proliferation and apoptosis Cell. Mol. Life Sci. 61 2004 1475 1484
4. R. Lotan Retinoids in cancer chemoprevention FASEB J. 10 1996 1031 1039
5. D.R. Shalinsky, E.D. Bischoff, M.L. Gregory, M.M. Gottardis, J.S. Hayes, W.W. Lamph, R.A. Heyman, M.A. Shirley, T.A. Cooke, P.J.A. Davies, and V. Thomazy Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice Cancer Res. 55 1995 3183 3191
6. J.R.F. Muindi, S.R. Frankel, C. Huselton, F. DeGrazia, W.A. Garland, C.W. Young, and R.P. Warrell Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia Cancer Res. 52 1992 2138 2142
7. S.R. Frankel, A. Eardley, G. Lauwers, M. Weiss, and R.P. Warrell Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia Ann. Intern. Med. 117 1992 292 296
8. C.C. Achkar, J.M. Bentel, J.F. Boylan, H.I. Scher, L.J. Gudas, and W.H. Miller Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice Drug Metab. Dispos. 22 1994 451 458
9. S. Walder, E.L. Schwartz, H. Haynes, R. Rameau, A. Quish, J. Mandeli, R. Gallagher, S. Hallam, A. Fields, G. Goldberg, F. McGill, S. Jennings, R.C. Wallach, and C.D. Runowicz All-trans retinoic acid and interferon-α-2a in patients with metastatic or recurrent carcinoma of the uterine cervix Cancer 79 1997 1574 1580
10. Y. Choi, S.Y. Kim, S.H. Kim, J. Yang, K. Park, and Y. Byun Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft Int. J. Cancer 107 2003 145 148
11. Y. Choi, S.Y. Kim, S.H. Kim, T.G. Park, H.T. Moon, and Y. Byun In vivo biocompatibility studies of poly(d,l-lactide)/poly(ethylene glycol)-poly(l- lactide) microspheres containing all-trans-retinoic acid J. Biomater. Sci., Polym. Ed. 13 2002 301 322
12. A.A. Sharkaway, B. Klitzman, G.A. Truskey, and W.M. Reichert Engineering the tissue which encapsulates subcutaneous implants: I. Diffusion properties J. Biomed. Mater. Res. 37 1997 401 412
13. R.K. Randolph, and M. Simon Dermal fibroblasts actively metabolize retinoic acid but not retinol J. Invest. Dermatol. 111 1998 478 484
14. J.M. Anderson, H. Nives, J. Pelagalli, L.S. Olanoff, and R.D. Jones The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems J. Biomed. Mater. Res. 15 1981 889 902
15. K. Seibert, J. Masferrer, Y. Zhang, K. Leahy, S. Hauser, J. Gierse, C. Koboldt, G. Anderson, M. Bremer, and S. Gregory Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase Adv. Prostaglandin Thromboxane Leukotriene Res. 23 1995 125 127
16. C.S. Williams, M. Mann, and R.N. Dubois The role of cyclooxygenases in inflammation, cancer and development Oncogene 18 1999 7908 7916
17. A. Schmassmann, B.M. Peskar, C. Stettler, P. Netzer, T. Stroff, B. Flogerzi, and F. Halter Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats Br. J. Pharmacol. 123 1998 795 804
18. C.J. Hawkey COX-2 inhibitors Lancet 353 1999 307 314
19. J.A. Mitchell, and T.D. Warner Cyclooxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy Br. J. Pharmacol. 128 1999 1121 1132
20. G. Coppelli, E. Guaita, S. Spaggiari, and G. Coruzzi Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat Dig. Liver Dis. 36 2004 265 270
21. K. Igarashi, J.-T. Woo, and P.H. Stern Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro Biochem. Pharmacol. 63 2002 523 532
22. Y. Choi, S.Y. Kim, S.H. Kim, K.-S. Lee, C. Kim, and Y. Byun Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres Int. J. Pharm. 215 2001 67 81
23. M.M. Tomayko, and P. Reynolds Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother. Pharmacol. 24 1989 148 154
24. K. Yamaguchi, and J.M. Anderson In vivo biocompatibility studies of Medisorb® 65/35 d,l-lactide/glycolide copolymer microspheres J. Control. Release 19 1992 299 314
25. C.J.L. Buggé, L.C. Rodriguez, and F.M. Vane Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography J. Pharm. Biomed. Anal. 3 1985 269 277
26. J. Bánóczy, and A. Csiba Occurrence of epithelial dysplasia in oral leukoplakia Oral Surg. 42 1976 766 774
27. P. Jussara, D.C. Shirley, D.R. Rogerio, and Q.R. Gustavo Injection of all-trans retinoic acid for treatment of thin wrinkles Aesthet. Plast. Surg. 21 1997 196 204
28. E. Schwartz, F.A. Cruickshank, J.A. Mezick, and L.H. Kligman Topical all-trans retinoic acid stimulates collagen synthesis in vivo J. Invest. Dermatol. 96 1991 975 978
29. H. Lateef, M.J. Stevens, and J. Varani All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture Am. J. Pathol. 165 2004 167 174
30. A.E. Postlethwaite, L.B. Lachman, and A.H. Kang Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells Arthritis Rheum. 27 1984 995 1001
31. M. Abe, M. Kurosawa, O. Ishikawa, and Y. Miyachi Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production J. Allergy Clin. Immunol. 106 2000 S78 S84
32. L.C. McSorley, and A.K. Daly Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation Biochem. Pharmacol. 60 2000 517 526
33. J. Marill, T. Cresteil, M. Lanotte, and G.G. Chabot Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites Mol. Pharmacol. 58 2000 1341 1348
34. W.J. Ray, G. Bain, M. Yao, and D.I. Gottlieb CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family J. Biol. Chem. 272 1997 18702 18708
35. H. Chen, A.G. Fantel, and M.R. Juchau Catalysis of the 4-hydroxylation of retinoic acid by CYP3a7 in human fetal hepatic tissues Drug Metab. Dispos. 28 2000 1051 1057
36. C. Tang, M. Shou, Q. Mei, T.H. Rushmore, and A.D. Rodrigues Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenases-II inhibitor J. Pharmacol. Exp. Ther. 293 2000 453 459
37. J.M. Nauta, J.L.N. Roodenburg, P.G.J. Nikkels, M.J.H. Witjes, and A. Vermey Comparison of epithelial dysplasia-the 4-NQO rat palate model and human oral mucosa Int. J. Oral Maxillofac. Surg. 24 1995 53 58
38. K. Wallenius, and U. Lekholm Oral cancer in rats induced by the water soluble carcinogen 4-nitroquinoline 1-oxide Odontol. Rev. 24 1973 39 48
39. D.B. Windhorst, and T. Nigra General clinical toxicology of oral retinoids J. Am. Acad. Dermatol. 6 1982 675 682
40. R.S. Larson, and M.S. Tallman Retinoic acid syndrome: manifestations, pathogenesis, and treatment Best Pract. Res., Clin. Haematol. 16 2003 453 461
41. Y. Choi, C. Lee, K. Park, S.Y. Kim, S.H. Kim, S. Han, S.H. Kim, and Y. Byun Subacute toxicity of all-trans-retinoic acid loaded biodegradable microspheres in rats Drug Dev. Res. 59 2003 326 332
42. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, and M.J. Thun Cancer statistics Ca-Cancer J. Clin. 54 2004 8 29
43. A. Jemal, A. Thomas, T. Murray, and M. Thun Cancer statistics Ca-Cancer J. Clin. 52 2002 23 47